Consistent with in vitro observations, EO771 cell-inoculated C57BL/6 mice revealed that the daily systemic administration of RANKL CM elevated the size and weight of mammary tumors in 14 days compared to the placebo mice that received the daily administration of PBS (Figure 1G). The gene discussed is TNFSF11; the disease is breast cancer.